

Dirk Bier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2027104/publications.pdf>

Version: 2024-02-01

33
papers

1,027
citations

759233

12
h-index

414414

32
g-index

36
all docs

36
docs citations

36
times ranked

954
citing authors

#	ARTICLE	IF	CITATIONS
1	Recovery from wernicke's aphasia: A positron emission tomographic study. <i>Annals of Neurology</i> , 1995, 37, 723-732.	5.3	570
2	Synthesis and Evaluation of No-Carrier-Added 8-Cyclopentyl-3-(3-[¹⁸ F]fluoropropyl)-1-propylxanthine ([¹⁸ F]CPFPX): A Potent and Selective A1-Adenosine Receptor Antagonist for in Vivo Imaging. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 5150-5156.	6.4	76
3	Distribution of photoassimilates in the pea plant: chronology of events in non-fertilized ovaries and effects of gibberellic acid. <i>Planta</i> , 1989, 180, 53-60.	3.2	34
4	Quantification of Cerebral A1 Adenosine Receptors in Humans using [¹⁸ F]CPFPX and PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2004, 24, 323-333.	4.3	33
5	Synthesis and Evaluation of 7-amino-2-(2(3-furyl)-5-phenylethylamino-oxazolo[5,4-d]pyrimidines as potential A2A adenosine receptor antagonists for positron emission tomography (PET). <i>European Journal of Medicinal Chemistry</i> , 2006, 41, 7-15.	5.5	33
6	METABOLISM OF THE A1 ADENOSINE RECEPTOR POSITRON EMISSION TOMOGRAPHY LIGAND [¹⁸ F]8-CYCLOPENTYL-3-(3-FLUOROPROPYL)-1-PROPYLXANTHINE ([¹⁸ F]CPFPX) IN RODENTS AND HUMANS. <i>Drug Metabolism and Disposition</i> , 2006, 34, 570-576.	3.3	28
7	Metabolism of the A1 adenosine receptor PET ligand [¹⁸ F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. <i>Nuclear Medicine and Biology</i> , 2006, 33, 891-898.	0.6	27
8	Quantification of cerebral A1 adenosine receptors in humans using [¹⁸ F]CPFPX and PET: an equilibrium approach. <i>NeuroImage</i> , 2005, 24, 1192-1204.	4.2	25
9	Autoradiographic comparison of in vitro binding characteristics of various tritiated adenosine A2A receptor ligands in rat, mouse and pig brain and first ex vivo results. <i>European Journal of Pharmacology</i> , 2009, 616, 107-114.	3.5	16
10	Collision-induced dissociation studies of caffeine in positive electrospray ionisation mass spectrometry using six deuterated isotopomers and one N1-ethylated homologue. <i>Rapid Communications in Mass Spectrometry</i> , 2013, 27, 885-895.	1.5	16
11	Binding of tritiated and radioiodinated ZM241,385 to brain A2A adenosine receptors. <i>Nuclear Medicine and Biology</i> , 2004, 31, 173-177.	0.6	14
12	New potent A1 adenosine receptor radioligands for positron emission tomography. <i>Nuclear Medicine and Biology</i> , 2017, 44, 69-77.	0.6	12
13	Hypericin and its radio iodinated derivatives – A novel combined approach for the treatment of pediatric alveolar rhabdomyosarcoma cells in vitro. <i>Photodiagnosis and Photodynamic Therapy</i> , 2020, 29, 101588.	2.6	12
14	In vivo imaging of rat brain A1 adenosine receptor occupancy by caffeine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1440-1440.	6.4	10
15	Tritium-labelled 8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine ([³ H]CPFPX), a potent and selective antagonist for the A1 adenosine receptor. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2003, 46, 365-372.	1.0	10
16	Derivatives of 4,6-diamino-1,2-dihydro-2-phenyl-1,2,4-triazolo[4,3-a]quinoxalin-2H-1-one: potential antagonist ligands for imaging the A2A adenosine receptor by positron emission tomography (PET). <i>European Journal of Medicinal Chemistry</i> , 2005, 40, 421-437.	5.5	10
17	Synthesis of the Main Metabolite in Human Blood of the A ₁ Adenosine Receptor Ligand [¹⁸ F]CPFPX. <i>Organic Letters</i> , 2009, 11, 4266-4269.	4.6	10
18	Relevance of In Vitro Metabolism Models to PET Radiotracer Development: Prediction of In Vivo Clearance in Rats from Microsomal Stability Data. <i>Pharmaceuticals</i> , 2019, 12, 57.	3.8	10

#	ARTICLE	IF	CITATIONS
19	Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A2A receptor ligands. <i>European Journal of Medicinal Chemistry</i> , 2021, 214, 113214.	5.5	9
20	First no-carrier-added radioselenation of an adenosine-A1 receptor ligand. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2004, 47, 415-427.	1.0	8
21	[¹⁸ F]ALX5406: A Brain-Penetrating Prodrug for GlyT1-Specific PET Imaging. <i>ACS Chemical Neuroscience</i> , 2021, 12, 3335-3346.	3.5	8
22	Delivery of the Radionuclide ¹³¹ I Using Cationic Fusogenic Liposomes as Nanocarriers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 457.	4.1	7
23	Radiochemical synthesis of [¹²³ I]2-iodo-lisuride for dopamine D2-receptor studies. <i>Nuclear Medicine and Biology</i> , 1996, 23, 373-376.	0.6	6
24	Efficient synthesis of [¹⁸ F]FPyME: A new approach for the preparation of maleimide-containing prosthetic groups for the conjugation with thiols. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2017, 60, 87-92.	1.0	6
25	Influence of incubation conditions on microsomal metabolism of xanthine-derived A1 adenosine receptor ligands. <i>Journal of Pharmacological and Toxicological Methods</i> , 2019, 95, 16-26.	0.7	6
26	Rapid Urinary Iodide Test. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1007-1012.	3.6	6
27	Evaluation of radioiodinated 8-Cyclopentyl-3-[(E)-3-iodoprop-2-en-1-yl]-1-propylxanthine ([¹²⁵ I]CPIPX) as a new potential A1 adenosine receptor antagonist for SPECT. <i>Nuclear Medicine and Biology</i> , 2003, 30, 661-668.	0.6	5
28	Synthesis and Pharmacological Evaluation of Identified and Putative Metabolites of the A ₁ Adenosine Receptor Antagonist 8-(3-(2-fluoropropyl)-1-propylxanthine (CPFPX). <i>ChemMedChem</i> , 2017, 12, 770-784.		3
29	Imaging of Adenosine Receptors. , 2014, , 181-198.		2
30	Influence of binding affinity and blood plasma level on cerebral pharmacokinetics and PET imaging characteristics of two novel xanthine PET radioligands for the A1 adenosine receptor. <i>Nuclear Medicine and Biology</i> , 2020, 82-83, 1-8.	0.6	1
31	Development and Evaluation of a Versatile Receptor-Ligand Binding Assay Using Cell Membrane Preparations Embedded in an Agarose Gel Matrix and Evaluation with the Human Adenosine A1 Receptor. <i>Assay and Drug Development Technologies</i> , 2020, 18, 328-340.	1.2	1
32	Species Differences in Microsomal Metabolism of Xanthine-Derived A1 Adenosine Receptor Ligands. <i>Pharmaceuticals</i> , 2021, 14, 277.	3.8	1
33	Preparation of 5-[¹³¹ I]iodotubercidin for the detection of adenosine kinase. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2020, 326, 1691-1697.	1.5	0